Newton, Massachusetts – September 3, 2013 – NeuroHealing Pharmaceuticals, a private clinical stage company developing drug treatments for individuals with neuro-rehabilitation needs, today announced the appointment of Mark Leuchtenberger to the company’s Board of Directors. Mark Leuchtenberger was most recently the President & CEO of Rib-X Pharmaceuticals until its acquisition by Vatera Healthcare in January 2013. Previously Mr. Leuchtenberger served as the President & CEO of Targanta Therapeutics from September 2006 until its acquisition by The Medicines Company in February 2009. He served as the President & CEO of Therion Biologics from 2002 to 2006. Mr. Leuchtenberger also served as Vice President of International of Biogen from 1999 to 2002, where he expanded international commercial operations to fifteen countries and distributor sales to 50 countries. He joined Biogen in 1990 as Product Manager and was responsible for managing the late-stage development, registration, marketing and North American launch of the company’s first commercial product Avonex®, now a $3 billion product. During his tenure at Biogen, he held several senior positions, including VP of Sales, Marketing and Business Development where he oversaw Biogen‘s global market, licensing and strategic partnership activities. Prior to Biogen, he served as a Senior Consultant of Bain & Co. specializing in healthcare. He is a past Chairman of the MassBio Board of Directors and currently serves as a trustee of Beth Israel Deaconess Medical Center in Boston. He is a cofounder of Albor Biologics and Alvos Therapeutics (acquired by Arrowhead Research Corp). Mr. Leuchtenberger holds an MBA from the Yale School of Management and a BA in English from Wake Forest University. “We are very pleased to welcome Mr. Leuchtenberger to our Board. Mark is an experienced biopharmaceutical executive with a significant track record in building and managing successful high-growth organizations. He has extensive experience in developing and commercializing new therapeutics, business development and licensing, with recent success in private funding rounds, IPO, and M&A negotiations,” commented Neal M. Farber, CEO of NeuroHealing. “NeuroHealing is an exciting early stage company with the potential to make a real difference in the lives of patients with significant neurological pathologies,” stated Mr. Leuchtenberger. “I believe the company has put together the critical ingredients for successful development and commercialization of their product candidates, and I look forward to working with the Board and the management team to make this a reality.” About NeuroHealing Pharmaceuticals NeuroHealing Pharmaceuticals, Inc. is a clinical stage private company developing innovative treatments for specialty indications based on repositioning neurologically active compounds. Clinical stage programs include: NH001 (phase II), a dopaminergic agent to help post traumatic brain injury patients to emerge from a coma, vegetative or minimally consciousness state; NH004 (phase II), an anticholinergic agent in convenient thin film delivery to help treat NEUROHEALING PHARMACEUTICALS INC. 617. 965.0872 – WWW.NEUROHEALING.COM P.O. BOX 238 . WABAN , MA 02 468 Parkinson’s and other patients with movement disorders suffering from sialorrhea (drooling); and NH02D, a neurologically active compound to treat premature ejaculation.

About the author